Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen Berenson
Co-founder and director Robert Langer also to retire from the Moderna Board; recruitment efforts ongoing for his replacement
Read MoreBioTech Medics, Inc. (OTC PINK:BMCS) and its subsidiary Commodity Vault are pleased to announce that the firms have created the architecture for our RWA Tokenization Trading Platform that includes, tokens, various commodities, verified blockchains, white papers, apps, wallets, websites, stocks and strategic partnerships all of these components, and more encompass our ecosystem
Read MoreWebcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast
Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS Ambassadors - cancer survivors who understand the realities of cancer and are no longer willing to accept debilitating side effects of cancer treatments as an acceptable trade-off for survival
Cancer patients with diarrhea are 40% more likely to discontinue their therapy; oral mucositis affects up to 40% of patients undergoing chemotherapy and approximately 90% of those receiving chemoradiation for head and neck cancers, with more than one-third of patients discontinuing cancer treatment because of the condition
Read More- STAR-1 topline results expected in first quarter of 2025 -
- About 30 million acne patients seek treatment in the U.S. each year -
- DMT310, if approved, could be the first once-weekly topical product for the treatment of acne -
Read MorePre-clinical study to explore use of MODD1 pump as a delivery system for FDA-approved, short acting peptides, as a personalized alternative for people who discontinue long-acting GLP-1 formulations
Read More
New patents issued for core rare disease target indications for crofelemer
Napo has approximately 200 patents issued and pending
Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with results expected in 2024 and 2025
Read MoreDuane Boise, President of MMJ BioPharma Cultivation, stated, "I think most Americans want judges who don't mind telling the truth and don't mind saying we're wrong. Unlike the DEA's arrogant attitude of, if we make a mistake, we won't be called on it, however MMJ is doing exactly that. The most immature thing you can do is say, 'no, no, I didn't make a mistake.' The mature thing to do, that all adults learn to do in this country is to say, 'oops, that was a mistake. I'm going to fix it. I'm sorry.'"
Read More
